Keynote-240. Nct02702401) compared pembrolizumab plus best supportive care (bsc) to bsc alone in 413 patients. The randomized phase iii keynote 240 study enrolled adult patients with a confirmed diagnosis of advanced hepatocellular carcinoma who experienced.
The randomized phase iii keynote 240 study enrolled adult patients with a confirmed diagnosis of advanced hepatocellular carcinoma who experienced. Nct02702401) compared pembrolizumab plus best supportive care (bsc) to bsc alone in 413 patients.